BCOP (BOARD CERTIFIED ONCOLOGY PHARMACIST) CERTIFICATION EXAMINATION
COMPLETE PRACTICE EXAM QUESTIONS AND ANSWERS | COMPREHENSIVE STUDY
GUIDE | UPDATED 2026/2027
Examiner/Administrator: Board of Pharmacy Specialties (BPS)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
BOARD CERTIFIED ONCOLOGY PHARMACIST (BCOP)
CERTIFICATION EXAMINATION
2026/2027 EDITION
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
COMPLETE PRACTICE EXAM
120 MULTIPLE-CHOICE QUESTIONS
PASSING SCORE: Determined using scaled scoring methodology
TESTING TIME: 4 HOURS
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TABLE OF CONTENTS
1. Cancer Biology & Molecular Oncology
2. Antineoplastic Pharmacology
3. Hematologic Malignancies
4. Solid Tumor Management
5. Supportive Care & Symptom Management
6. Oncology Pharmacokinetics & Therapeutic Monitoring
7. Oncology Guidelines & Evidence-Based Practice
8. Oncology Practice Management & Patient Safety
9. Clinical Research & Biostatistics
10. Professional Practice, Ethics & Regulatory Standards
BOARD OF PHARMACY SPECIALTIES (BPS) || ALIGNED WITH CURRENT BCOP
EXAMINATION BLUEPRINTS || ONCOLOGY PHARMACY COMPETENCY-BASED
ASSESSMENT || PROFESSIONAL STUDY GUIDE || VERIFIED PRACTICE QUESTIONS ||
,COMPREHENSIVE CERTIFICATION PREPARATION || PREPARED FOR ADVANCED
ONCOLOGY PHARMACY PRACTICE || PROFESSIONAL EXAMINATION USE
Questions 1–8: Cancer Biology & Molecular Oncology
QUESTION 1. A 56-year-old patient with metastatic non-small cell lung cancer is found
to have an activating EGFR exon 19 deletion. Which treatment strategy is most
appropriate as first-line systemic therapy?
A. Platinum-based chemotherapy alone
B. EGFR tyrosine kinase inhibitor therapy
C. PD-1 inhibitor monotherapy regardless of biomarker status
D. VEGF inhibitor monotherapy
Correct Answer: B. EGFR tyrosine kinase inhibitor therapy
Explanation: Patients with sensitizing EGFR mutations derive superior progression-free
survival and response rates from EGFR-targeted therapy compared with conventional
chemotherapy. Platinum chemotherapy remains appropriate after resistance or when
targeted therapy is unsuitable. Immunotherapy alone has limited efficacy in many EGFR-
mutated tumors, while VEGF inhibitor monotherapy is not considered standard first-line
treatment.
QUESTION 2. Which biomarker is most predictive of response to trastuzumab therapy
in breast cancer?
A. HER2 overexpression or gene amplification
B. KRAS mutation
C. BRAF V600E mutation
D. Microsatellite instability
Correct Answer: A. HER2 overexpression or gene amplification
Explanation: Trastuzumab specifically targets HER2-positive malignancies confirmed by
validated testing. KRAS, BRAF, and MSI status guide therapy in other malignancies but do
not determine trastuzumab eligibility.
,QUESTION 3. A pharmacist reviews a pathology report showing high microsatellite
instability (MSI-H). This finding most strongly suggests benefit from which class of
therapy?
A. Alkylating agents
B. Anti-CD20 monoclonal antibodies
C. Immune checkpoint inhibitors
D. Taxanes
Correct Answer: C. Immune checkpoint inhibitors
Explanation: MSI-H tumors possess increased neoantigen formation and often
demonstrate improved responses to immune checkpoint inhibition. Alkylators, taxanes,
and anti-CD20 antibodies are selected for different disease characteristics rather than
MSI status.
QUESTION 4. Which hallmark of cancer allows malignant cells to continue proliferating
despite genomic instability?
A. Sustained proliferative signaling
B. Reduced angiogenesis
C. Enhanced apoptosis
D. Permanent cellular senescence
Correct Answer: A. Sustained proliferative signaling
Explanation: Cancer cells maintain autonomous growth through continuous activation
of proliferative pathways. Enhanced apoptosis and permanent senescence suppress
malignancy rather than promote it, while reduced angiogenesis would impair tumor
growth.
QUESTION 5. A patient develops resistance to a targeted kinase inhibitor through
acquisition of a secondary mutation affecting the drug-binding site. This represents:
, A. Pharmacokinetic failure only
B. Primary resistance
C. Acquired resistance
D. Immune-mediated toxicity
Correct Answer: C. Acquired resistance
Explanation: Secondary mutations that develop after initial treatment response
represent acquired resistance. Primary resistance occurs before treatment begins.
Pharmacokinetic failure and immune toxicity describe different mechanisms.
QUESTION 6. Which process primarily enables metastatic spread of epithelial cancers?
A. Epithelial-mesenchymal transition (EMT)
B. Increased erythropoiesis
C. Complement activation
D. Platelet destruction
Correct Answer: A. Epithelial-mesenchymal transition (EMT)
Explanation: EMT facilitates invasion, migration, and dissemination of malignant
epithelial cells. The remaining options are unrelated to the biologic mechanisms
responsible for metastasis.
QUESTION 7. Tumor mutational burden (TMB) is primarily evaluated because it may
predict:
A. Cisplatin nephrotoxicity
B. Response to immunotherapy
C. Anthracycline cardiotoxicity
D. Vincristine neuropathy
Correct Answer: B. Response to immunotherapy
COMPLETE PRACTICE EXAM QUESTIONS AND ANSWERS | COMPREHENSIVE STUDY
GUIDE | UPDATED 2026/2027
Examiner/Administrator: Board of Pharmacy Specialties (BPS)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
BOARD CERTIFIED ONCOLOGY PHARMACIST (BCOP)
CERTIFICATION EXAMINATION
2026/2027 EDITION
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
COMPLETE PRACTICE EXAM
120 MULTIPLE-CHOICE QUESTIONS
PASSING SCORE: Determined using scaled scoring methodology
TESTING TIME: 4 HOURS
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TABLE OF CONTENTS
1. Cancer Biology & Molecular Oncology
2. Antineoplastic Pharmacology
3. Hematologic Malignancies
4. Solid Tumor Management
5. Supportive Care & Symptom Management
6. Oncology Pharmacokinetics & Therapeutic Monitoring
7. Oncology Guidelines & Evidence-Based Practice
8. Oncology Practice Management & Patient Safety
9. Clinical Research & Biostatistics
10. Professional Practice, Ethics & Regulatory Standards
BOARD OF PHARMACY SPECIALTIES (BPS) || ALIGNED WITH CURRENT BCOP
EXAMINATION BLUEPRINTS || ONCOLOGY PHARMACY COMPETENCY-BASED
ASSESSMENT || PROFESSIONAL STUDY GUIDE || VERIFIED PRACTICE QUESTIONS ||
,COMPREHENSIVE CERTIFICATION PREPARATION || PREPARED FOR ADVANCED
ONCOLOGY PHARMACY PRACTICE || PROFESSIONAL EXAMINATION USE
Questions 1–8: Cancer Biology & Molecular Oncology
QUESTION 1. A 56-year-old patient with metastatic non-small cell lung cancer is found
to have an activating EGFR exon 19 deletion. Which treatment strategy is most
appropriate as first-line systemic therapy?
A. Platinum-based chemotherapy alone
B. EGFR tyrosine kinase inhibitor therapy
C. PD-1 inhibitor monotherapy regardless of biomarker status
D. VEGF inhibitor monotherapy
Correct Answer: B. EGFR tyrosine kinase inhibitor therapy
Explanation: Patients with sensitizing EGFR mutations derive superior progression-free
survival and response rates from EGFR-targeted therapy compared with conventional
chemotherapy. Platinum chemotherapy remains appropriate after resistance or when
targeted therapy is unsuitable. Immunotherapy alone has limited efficacy in many EGFR-
mutated tumors, while VEGF inhibitor monotherapy is not considered standard first-line
treatment.
QUESTION 2. Which biomarker is most predictive of response to trastuzumab therapy
in breast cancer?
A. HER2 overexpression or gene amplification
B. KRAS mutation
C. BRAF V600E mutation
D. Microsatellite instability
Correct Answer: A. HER2 overexpression or gene amplification
Explanation: Trastuzumab specifically targets HER2-positive malignancies confirmed by
validated testing. KRAS, BRAF, and MSI status guide therapy in other malignancies but do
not determine trastuzumab eligibility.
,QUESTION 3. A pharmacist reviews a pathology report showing high microsatellite
instability (MSI-H). This finding most strongly suggests benefit from which class of
therapy?
A. Alkylating agents
B. Anti-CD20 monoclonal antibodies
C. Immune checkpoint inhibitors
D. Taxanes
Correct Answer: C. Immune checkpoint inhibitors
Explanation: MSI-H tumors possess increased neoantigen formation and often
demonstrate improved responses to immune checkpoint inhibition. Alkylators, taxanes,
and anti-CD20 antibodies are selected for different disease characteristics rather than
MSI status.
QUESTION 4. Which hallmark of cancer allows malignant cells to continue proliferating
despite genomic instability?
A. Sustained proliferative signaling
B. Reduced angiogenesis
C. Enhanced apoptosis
D. Permanent cellular senescence
Correct Answer: A. Sustained proliferative signaling
Explanation: Cancer cells maintain autonomous growth through continuous activation
of proliferative pathways. Enhanced apoptosis and permanent senescence suppress
malignancy rather than promote it, while reduced angiogenesis would impair tumor
growth.
QUESTION 5. A patient develops resistance to a targeted kinase inhibitor through
acquisition of a secondary mutation affecting the drug-binding site. This represents:
, A. Pharmacokinetic failure only
B. Primary resistance
C. Acquired resistance
D. Immune-mediated toxicity
Correct Answer: C. Acquired resistance
Explanation: Secondary mutations that develop after initial treatment response
represent acquired resistance. Primary resistance occurs before treatment begins.
Pharmacokinetic failure and immune toxicity describe different mechanisms.
QUESTION 6. Which process primarily enables metastatic spread of epithelial cancers?
A. Epithelial-mesenchymal transition (EMT)
B. Increased erythropoiesis
C. Complement activation
D. Platelet destruction
Correct Answer: A. Epithelial-mesenchymal transition (EMT)
Explanation: EMT facilitates invasion, migration, and dissemination of malignant
epithelial cells. The remaining options are unrelated to the biologic mechanisms
responsible for metastasis.
QUESTION 7. Tumor mutational burden (TMB) is primarily evaluated because it may
predict:
A. Cisplatin nephrotoxicity
B. Response to immunotherapy
C. Anthracycline cardiotoxicity
D. Vincristine neuropathy
Correct Answer: B. Response to immunotherapy
